Barclay Phillips Purchases IMUX Shares in Recent Insider Activity
Barclay Phillips and other insiders bought IMUX shares on June 29, 2026.
Key Points
- Barclay Phillips bought 25,370 shares of IMUX on June 29, 2026, as part of recent insider activity.
- Shares of IMUX traded near $15.30 on Tuesday, with a range of peers adjusting their positions.
- Analysts including B. Riley Securities and HC Wainwright & Co. maintained buy ratings with targets of $27.00 and $22.00, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Barclay Phillips recently purchased 25,370 shares of IMUX on June 29, 2026. This insider transaction occurred alongside several others, indicating a busy period for company insiders.
Insider Buying and Selling at Immunic, Inc.
On June 29, 2026, multiple insiders at IMUX were active in the market. Apart from Barclay Phillips, Jon Congleton acquired 50,740 shares, while Jason Tardio, President and COO, bought 253,000 shares. Glenn Whaley, the Chief Financial Officer, added 120,000 shares to his holdings. Also, Joerg Neermann and Tamar Howson each bought 25,370 shares, and Daniel Vitt acquired 445,000 shares. None of these transactions were part of a pre-planned trading program.
Other Institutional Activity in IMUX
Several institutional investors made significant moves regarding their IMUX holdings. Aberdeen Group PLC reduced its position by 7,419,547 shares, leaving it with 824,394 shares valued at about $9.15 million. BVF Inc/IL similarly cut its holdings by 6,887,675 shares, ending with 765,297 shares worth approximately $8.49 million. Avidity Partners Management LP also decreased its position by 4,029,470 shares, holding 669,941 shares valued at roughly $7.44 million. Meanwhile, Vanguard Capital Management LLC and Soleus Capital Management, L.P. opened new positions with 513,832 and 450,000 shares, valued at $5.70 million and $4.99 million, respectively.
Immunic, Inc. Stock Up 0.1%
Shares of IMUX traded near $15.30 on Tuesday. The stock has experienced fluctuations, with a 52-week low of $10.00 and a high of $20.00. Investors keep an eye on its performance, considering the recent insider activities and institutional movements.
$IMUX stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Analyst firms have been active in setting targets for IMUX. On May 22, 2026, B. Riley Securities maintained a buy rating with a price target of $27.00. HC Wainwright & Co. also maintained a buy rating, targeting $22.00 on April 30, 2026. Stifel initiated coverage with a buy rating and a $2.50 target on April 17, 2026. The overall consensus remains positive with a focus on growth potential.
Bottom Line
The recent insider transactions at IMUX, including Barclay Phillips' purchase, highlight increased insider confidence in the company. While the stock price remains volatile, the activity from both insiders and institutions suggests a dynamic period for IMUX. Investors often watch these moves for insights, but it's essential to remember that these filings are backward-looking and may not reflect the current situation.
Get Immunic, Inc. alerts
New 13F filings, insider trades, and analyst moves on $IMUX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.